ArticleJournal of oncology2020
Patterns and Prevalence of Germline
Article in Journal of oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 15 citations in OpenAlex.
- Reclassification ofBiomolecules & biomedicine · 2026Article
- Mutant soluble Interleukin-6 receptor as a potential agent for inhibiting cell migration and inducing apoptosis in a breast cancer cell line.Molecular biology reports · 2025Article
- Mutational spectrum of BRCA genes in Egyptian patients with breast cancer.Scientific reports · 2025Article
- From Pioneering Discoveries to Innovative Therapies: A Journey Through the History and Advancements of Nanoparticles in Breast Cancer Treatment.Breast cancer (Dove Medical Press) · 2025Review
- BRCA1/2 potential founder variants in the Jordanian population: an opportunity for a customized screening panel.Hereditary cancer in clinical practice · 2023Review
- Prevalence and clinical implications of germline mutations among Jordanian patients with ovarian cancer. The Jordanian exploratory cancer genetics (Jo-ECAG) ovarian study.Molecular genetics & genomic medicine · 2023Article
- Pathogenic germline variants in patients with breast cancer: conversations across generations, practices and patients' attitude.Frontiers in genetics · 2023Article
- Guideline-Based, Multi-Gene Panel Germline Genetic Testing for at-Risk Patients with Breast Cancer.Breast cancer (Dove Medical Press) · 2023Article
- Mutational spectrum of BRCA1/2 genes in Moroccan patients with hereditary breast and/or ovarian cancer, and review of BRCA mutations in the MENA region.Breast cancer research and treatment · 2022Article
- Rates of Variants of Uncertain Significance Among Patients With Breast Cancer Undergoing Genetic Testing: Regional Perspectives.Frontiers in oncology · 2022Article
- Gail model utilization in predicting breast cancer risk in Egyptian women: a cross-sectional study.Breast cancer research and treatment · 2021Article
- Prevalence and predictors of germline BRCA1 and BRCA2 mutations among young patients with breast cancer in Jordan.Scientific reports · 2021Article
- Expanding the search for germline pathogenic variants for breast cancer. How far should we go and how high should we jump? The missed opportunity!Oncology reviews · 2021Article
- Patterns and Prevalence ofCancer management and research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeKnowledge of
methods
resultsA total of 517 patients, median age: 39 (range: 19-78) years, were enrolled. Among the whole group, 72 (13.9%) patients had pathogenic or likely pathogenic
conclusions
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.